Lifeward Ltd. (LFWD) Stock

Lifeward Ltd. (LFWD) is a Healthcare stock trading at $6.69 (as of 2026-06-18), with a market capitalization of $9.53M and a trailing P/E of -0.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Lifeward Ltd. designs, develops, and markets wearable robotic exoskeleton systems that provide hip and knee motion for people with spinal cord injury to stand, walk, turn, and navigate stairs. Its offerings include the ReWalk Exo-Suit and ReWalk Personal 6.0.

Valuation — source: SEC EDGAR (first-party)
Price$6.69
Market Cap$9.53M
P/E Ratio-0.3
EV / EBITDA-0.3
Price / Book3.09
Price / Sales0.93
DCF Value (model)$-185.93
DCF Upside vs Price-2879.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$22.03M
Net Margin-90.4%
Return on Equity-411.3%
Current Ratio2.40
Revenue Growth (YoY)-22.1%
EPS Growth (YoY)1356.5%
FCF Growth (YoY)-33.2%
Financial Health — source: SEC EDGAR
Altman Z-Score-18.66 (distress)
Valuation vs Sector & Industry
Stock P/E-0.3
Sector P/E (Healthcare)20.9
Industry P/E (Medical Equipment)31.7
vs Sector-101.4%
vs Industry-100.9%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderCITADEL ADVISORS LLC ($152287.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOWilliam Mark Grant
Employees80
CountryIL
IPO Date2014-09-12

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Sonoma Pharmaceuticals, Inc. (SNOA)
  • Nuwellis, Inc. (NUWE)
  • Bone Biologics Corporation (BBLG)
  • ENvue Medical, Inc. (FEED)
  • SeaStar Medical Holding Corporation (ICU)
  • Amundi Core MSCI Emerging Markets UCITS ETF EUR Dist (AEMD)
  • Bluejay Diagnostics, Inc. (BJDX)
  • Co-Diagnostics, Inc. (CODX)
LFWD earnings history · LFWD institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.